Syngene centre opens

    Syngene International, a subsidiary of Indian biotech Biocon, and US drugmaker Bristol-Myers Squibb (BMS) have opened a research-and-development centre in Bangalore.

    The 18,000-square-metre facility, which employs 270 researchers, helps advance BMS's discovery and early drug-development efforts. It will house 360 researchers by the end of the year and plans to ramp that number up to 450.

    Work at the facility will span the drug discovery and development process. Construction began in March 2007, when BMS and Biocon agreed to focus on integrated drug discovery and development capabilities at Syngene.

    Related links

    Related links

    Related links in Nature Research

    Biotechs feel the pain

    Related external links

    Bristol-Myers Squibb

    Biocon

    Rights and permissions

    Reprints and Permissions

    About this article

    Cite this article

    Syngene centre opens. Nature 458, 663 (2009). https://doi.org/10.1038/nj7238-663d

    Download citation

    Comments

    By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.